Taysha Gene Therapies (NASDAQ:TSHA) Earns Outperform Rating from Analysts at Wolfe Research

Wolfe Research initiated coverage on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research note released on Thursday morning, Marketbeat.com reports. The firm issued an outperform rating on the stock.

Several other analysts have also recently weighed in on TSHA. The Goldman Sachs Group raised their target price on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Pivotal Research set a $14.00 target price on Taysha Gene Therapies in a research note on Tuesday, June 23rd. BMO Capital Markets upped their target price on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the company an “outperform” rating in a report on Tuesday, June 23rd. Citizens Jmp reissued a “market outperform” rating and issued a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $12.77.

Taysha Gene Therapies Price Performance

TSHA opened at $5.02 on Thursday. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of -11.95 and a beta of 1.19. The stock’s 50-day moving average price is $5.79 and its 200 day moving average price is $5.66. Taysha Gene Therapies has a 12-month low of $2.71 and a 12-month high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, sell-side analysts expect that Taysha Gene Therapies will post -0.52 earnings per share for the current year.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the transaction, the insider owned 936,410 shares in the company, valued at approximately $5,843,198.40. This represents a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.48% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of hedge funds and other institutional investors have recently modified their holdings of TSHA. Polar Capital Holdings Plc raised its holdings in Taysha Gene Therapies by 49.8% during the fourth quarter. Polar Capital Holdings Plc now owns 7,931,403 shares of the company’s stock worth $43,623,000 after purchasing an additional 2,637,524 shares during the last quarter. Wellington Management Group LLP increased its position in Taysha Gene Therapies by 534.7% during the 2nd quarter. Wellington Management Group LLP now owns 3,975,605 shares of the company’s stock worth $27,074,000 after purchasing an additional 3,349,244 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Taysha Gene Therapies in the 4th quarter valued at about $20,471,000. ADAR1 Capital Management LLC raised its stake in Taysha Gene Therapies by 19.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,979,429 shares of the company’s stock valued at $13,318,000 after purchasing an additional 483,620 shares during the last quarter. Finally, Seven Fleet Capital Management LP lifted its holdings in Taysha Gene Therapies by 140.4% in the 2nd quarter. Seven Fleet Capital Management LP now owns 1,504,400 shares of the company’s stock valued at $9,940,000 after purchasing an additional 878,692 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company developing gene therapies for severe monogenic diseases of the central nervous system. The company focuses on disorders in which a missing or defective gene contributes to neurological disease and uses adeno-associated virus (AAV) vectors to deliver functional genetic material to targeted cells.

Taysha’s development programs have included TSHA-102, an investigational gene therapy for Rett syndrome, and earlier programs such as TSHA-120 for giant axonal neuropathy and TSHA-101 for GM1 gangliosidosis.